Novartis acquires Avidity in a $12B bet on RNA therapeutics for rare disease. A landmark deal in biopharma M&A and drug ...
Morning Brief host Julie Hyman tracks several of the day's top trending stock tickers, including Novartis' (NVS) move to buy ...
Swiss drugmaker Novartis on Sunday said it agreed to acquire U.S. biotech firm Avidity Biosciences for about $12 billion in ...
In laying out their respective plans Monday to launch new direct-to-patient (DTP) platforms paring down the prices of popular medicines in the U.S., Novartis and Boehringer Ingelheim are falling in ...
Novartis to acquire Avidity Biosciences for $12bn, boosting its RNA neuromuscular pipeline as pharma M&A heats up in the RNA ...
Swiss pharmaceutical giant Novartis announced Sunday it had agreed to buy Avidity Biosciences, valuing the US ...
Zacks Investment Research on MSN
Compared to Estimates, Novartis (NVS) Q3 Earnings: A Look at Key Metrics
For the quarter ended September 2025, Novartis (NVS) reported revenue of $13.91 billion, up 8.5% over the same period last year. EPS came in at $2.25, compared to $2.06 in the year-ago quarter. The ...
By Bhanvi Satija LONDON (Reuters) -Swiss drugmaker Novartis is exploring options to add more medicines to its ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback